January 02, 2026 08:11 pm (IST)
Follow us:
facebook-white sharing button
twitter-white sharing button
instagram-white sharing button
youtube-white sharing button
‘Epicentre of misgovernance’: Rahul Gandhi blasts Madhya Pradesh govt over deadly water contamination | After Mamdani's letter, 8 US lawmakers push 'fair trial' for Umar Khalid amid UAPA case | ‘Bad neighbours’: Jaishankar shreds Pakistan, defends India’s right to act against cross-border terror | New Year gift for rail passengers! PM Modi to flag off first Vande Bharat sleeper in January | ‘Rs 1 lakh for his tongue’: Shah Rukh Khan faces threats after KKR signs Mushtafizur Rahman amid violence against Hindus in Bangladesh | New Year horror in Switzerland: Dozens feared dead in Crans-Montana bar explosion | Tobacco stocks crushed as govt slaps fresh excise duty from Feb 1 | Vodafone Idea shares explode 10% after surprise settlement and govt relief boost | No third party involved: India govt sources refute China’s Operation Sindoor ceasefire claim | Amit Shah blasts TMC over border fencing; Mamata fires back on Pahalgam and Delhi blast
Chinese vaccine
Image: Unsplash

Pakistan says China's Sinopharm vaccine not recommended for people aged above 60

| @indiablooms | Feb 11, 2021, at 04:56 pm

The Chinese Sinopharm vaccine for Covid-19, which started being administered in Pakistan recently, is not recommended for people aged over 60, a top official said.

Speaking to reporters in Islamabad, Special Assistant to the Prime Minister on Health Dr Faisal Sultan was quoted as saying by Dawn News that the government's expert committee while considering the preliminary analysis of Sinopharm data had recommended that the vaccine be licensed for people aged 18-60 "at this stage".

"At this stage, the [committee] did not authorise the vaccine for people older than 60," he added.

When contacted by Dawn News about which vaccine would be used for people over 60 instead of Sinopharm's, Dr Sultan said the AstraZeneca vaccine would be used.

"When our Pakistani experts looked at the data, they were reasonably satisfied with the AstraZeneca data but felt that [based] on the presently available numbers for Sinopharm, the data did not justify its usage for those aged over 60," he said.

"The Chinese have also reiterated this restriction," he added.

Support Our Journalism

We cannot do without you.. your contribution supports unbiased journalism

IBNS is not driven by any ism- not wokeism, not racism, not skewed secularism, not hyper right-wing or left liberal ideals, nor by any hardline religious beliefs or hyper nationalism. We want to serve you good old objective news, as they are. We do not judge or preach. We let people decide for themselves. We only try to present factual and well-sourced news.

Support objective journalism for a small contribution.